Assignee profile:

Innate Pharma

City:

Marseille

Country:

France

Published Applications:

25

Last publication date:

2019-01-31

Patent Grants:

20

Last grant date:

2020-12-22

Top Inventors for applications by Innate Pharma

These are the the leading inventors for applications assigned to Innate Pharma:

Recent patent applications by Innate Pharma

Innate Pharma based in Marseille, FR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2019-01-31 ✅ Patent 10,870,700 granted on 2020-12-22
US20190031755A1
Chemistry; metallurgy

Neutralization of inhibitory pathways in lymphocytes

#2 | 2017-10-19 ✅ Patent 10,676,523 granted on 2020-06-09
US20170298131A1
Chemistry; metallurgy

Treatment regimens using anti-NKG2A antibodies

#3 | 2017-06-08 ✅ Patent 10,280,222 granted on 2019-05-07
US20170158763A1
Chemistry; metallurgy

Humanized antibodies with increased stability

#4 | 2016-02-18 ✅ Patent 9,708,403 granted on 2017-07-18
US20160046712A1
Chemistry; metallurgy

KIR-binding agents and methods of use thereof

#5 | 2015-06-18 ✅ Patent 9,427,478 granted on 2016-08-30
US20150165064A1
Human necessities

Enzymatic conjugation of polypeptides

#6 | 2015-05-21 ✅ Patent 9,944,712 granted on 2018-04-17
US20150140000A1
Chemistry; metallurgy

TLR3 binding agents

#7 | 2014-08-21
US20140234342A1
Chemistry; metallurgy

NKP46-MEDIATED NK CELL TUNING

#8 | 2014-08-21
US20140234323A1
Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR DETECTING TLR3

#9 | 2014-03-06
US20140065154A1
Human necessities

TLR3 BINDING AGENTS

#10 | 2013-07-25 ✅ Patent 9,717,803 granted on 2017-08-01
US20130189287A1
Chemistry; metallurgy

Enzymatic conjugation of polypeptides

#11 | 2012-12-06 ✅ Patent 8,715,667 granted on 2014-05-06
US20120308581A1
Chemistry; metallurgy

Methods of treating patients having TLR3-positive cancer

#12 | 2012-03-15 ✅ Patent 9,181,341 granted on 2015-11-10
US20120064081A1
Chemistry; metallurgy

Anti-KIR3D antibodies

#13 | 2012-02-09 ✅ Patent 9,388,246 granted on 2016-07-12
US20120034232A1
Chemistry; metallurgy

TLR3 binding agents

#14 | 2011-10-06 ✅ Patent 8,735,624 granted on 2014-05-27
US20110245534A1
Chemistry; metallurgy

Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same

#15 | 2011-09-01 ✅ Patent 8,273,541 granted on 2012-09-25
US20110212110A1
Chemistry; metallurgy

Compositions and methods for detecting TLR3

#16 | 2011-01-13 ✅ Patent 9,090,876 granted on 2015-07-28
US20110008335A1
Human necessities

Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

#17 | 2010-11-18
US20100291118A1
Chemistry; metallurgy

Class of Gamma Delta T Cells Activators and Use Thereof

#18 | 2009-03-26 ✅ Patent 8,119,775 granted on 2012-02-21
US20090081240A1
Chemistry; metallurgy

Human anti-KIR antibodies

#19 | 2008-12-04
US20080300222A1
Chemistry; metallurgy

Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization

#20 | 2008-11-06 ✅ Patent 9,447,185 granted on 2016-09-20
US20080274047A1
Chemistry; metallurgy

Compositions and methods for treating proliferative disorders

#21 | 2006-11-02 ✅ Patent 7,279,291 granted on 2007-10-09
US20060246068A1
Chemistry; metallurgy

Polypeptides having a triggering NK activity and biological applications

#22 | 2006-02-09 ✅ Patent 7,399,756 granted on 2008-07-15
US20060030546A1
Chemistry; metallurgy

Organo-phosphorous compounds for activating gamma/delta T cells

#23 | 2005-10-06 ✅ Patent 7,517,966 granted on 2009-04-14
US20050221438A1
Chemistry; metallurgy

Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same

#24 | 2005-07-21 ✅ Patent 7,138,243 granted on 2006-11-21
US20050159332A1
Chemistry; metallurgy

NTB-A, a surface molecule involved in natural killer cells activity

#25 | 2005-02-17 ✅ Patent 7,803,376 granted on 2010-09-28
US20050037002A1
Human necessities

Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

Also check out INNATE PHARMA's (Marseille, France) applicant profile with 21 patent applications submitted.

AssigneeID:

31607